Skip to main content
Caplight Logo









eKuore

eKuore

Private
ValenciaHealthcare & Life Scienceshttps://filetomob.com/

Last Round

Seed

Apr 3, 2020

Est. Valuation

$9.37M

Total Funding Raised

$3.17M

Company Overview

eKuore operates in Healthcare & Life Sciences and is based in Valencia. Its latest recorded funding round was a Seed round in April 2020.

eKuore is a health technology company that designs, develops, and markets mobile health devices, including wireless electronic stethoscopes for medical and veterinary use.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Telemedicine, Health IoT

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Pricing history

Caplight clients see full MarketPrice™ history and secondary transactions.

Book a demo

For institutional investors. Book with your work email.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

Momentum history

Caplight clients track how buyer interest and sentiment change over time.

Book a demo

For institutional investors. Book with your work email.

eKuore Comparables

Compare eKuore with similar companies based on industry and business-model similarity.

eKuore comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
M3DICINE
83%
Sonavi Labs, Inc.
82%
Sanolla
81%
Book a demo to see all comparables

For institutional investors. Book with your work email.

eKuore Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedApr 3, 2020
DebtMar 11, 2020
Early FundingMay 23, 2017
GrantJul 20, 2015
AngelOct 28, 2014
Book a demo to see all funding rounds

For institutional investors. Book with your work email.

eKuore Investors

Notable investors and investment history

eKuore investors
InvestorRounds
European CommissionGrant
BIGBAN Investors SpainAngel
Capital CellSeed

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 12, 2026

    Monthly visitors increased 37% MoM.

  • Jul 10, 2025

    Monthly visitors grew 4124% MoM, reaching 37K.

Book a demo to see all signals

For institutional investors. Book with your work email.

eKuore Filings

Explore SEC and related filing metadata, where available.

eKuore filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Book a demo

For institutional investors. Book with your work email.

Frequently Asked Questions

Common questions about eKuore's valuation, stock price, and market status.

Is eKuore a public or private company?

eKuore is a private company.

What is the current stock price of eKuore?

eKuore is a private company, so its shares have no public market price. Caplight tracks eKuore's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is eKuore worth (valuation)?

eKuore's valuation is estimated at $9.4M based on funding round data.

Can I buy eKuore stock?

eKuore shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was eKuore's last funding round?

eKuore's most recent funding round was Seed on April 3, 2020.

Who are the main investors in eKuore?

Key investors in eKuore include BIGBAN Investors Spain.

Will eKuore IPO soon?

No public IPO plans have been announced for eKuore.

How can I track eKuore secondary market activity?

Caplight tracks bids, offers, and trades in eKuore's shares on secondary markets.

Firmographic Details

HeadquartersValencia
Employee Range4
Year Founded2012
Last FundingApr 3, 2020

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Book a demo

For institutional investors. Book with your work email.

See something wrong or outdated?